Metropolis Healthcare posts Q1 FY25 at Rs. 38.1 Cr
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
Revenue from operations stood at Rs. 313.4 crore during Q1 FY25
This accelerates the clinical-to-commercial process timeline and enables customers to develop the right molecule
The inspection was concluded with zero observations
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
The campaign targets 63 endemic districts across Bihar, Jharkhand, Karnataka, Odisha, Telangana, and Uttar Pradesh
Our centers are performing as expected or even better
CN201 is a next generation CD3xCD19 bispecific antibody that augments and diversifies Merck’s pipeline, with potential applications in B-cell malignancies and autoimmune diseases
The International Society of Aesthetic Plastic Surgery reported that non-surgical procedures outnumbered surgical ones globally in 2020
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
Subscribe To Our Newsletter & Stay Updated